Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain
**Purpose:** To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. **Design and methods:** A Markov model was...
Main Authors: | Eva Tirado Mercier, Daniel Callejo Velasco, Marta Rubio Cabezas, Cristina Moretones Agut, Meritxell Granell Villalón |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | http://jheor.scholasticahq.com/article/9777-cost-effectiveness-analysis-of-radium-223-dichloride-in-metastatic-castration-resistant-prostate-cancer-patients-without-previous-chemotherapy-treatment-in-spain.pdf |
Similar Items
-
Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer
by: Renzulli II JF, et al.
Published: (2015-06-01) -
Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01) -
Radium 223 dichloride for prostate cancer treatment
by: Deshayes E, et al.
Published: (2017-09-01) -
Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
by: Kalevi Kairemo, et al.
Published: (2015-07-01) -
RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)